ID Biomedical Corporation Completes Enrollment for Fluviral Clinical Trial

ID Biomedical Corporation, a Canadian biotechnology company, has achieved a significant milestone in its efforts to bring a new influenza vaccine to the market. The company has completed the enrollment of 1,000 healthy adults for a clinical trial of its Fluviral vaccine, exceeding its original target of 300 subjects. This achievement is expected to support accelerated approval in the United States and pave the way for the company's vision to manufacture and ship influenza vaccine for the 2006-2007 season.

Key Takeaways:

• ID Biomedical has completed the enrollment of 1,000 subjects for its Fluviral clinical trial, a randomized, double-blind, comparator-controlled study designed to evaluate the safety and immunogenicity of the vaccine in healthy adults.
• The company has expanded the trial from 300 subjects to 1,000 healthy adults aged 18 to 64, achieving this milestone six weeks ahead of schedule.
• The Fluviral clinical trial in Canada has also been completed, enrolling 658 participants and evaluating the safety and immunogenicity of the vaccine in adults aged 50 to 64 and over 64 years.
• Data from both trials will be filed in support of U.S. licensure for the Fluviral vaccine.
• ID Biomedical is committed to developing innovative vaccine products and operates in research, development, manufacturing, sales, and marketing from its facilities in Canada and the U.S.

Statistics:

• 1,000 subjects enrolled in the Fluviral clinical trial in the United States.
• 658 subjects enrolled in the Fluviral clinical trial in Canada.
• The company completed the enrollment six weeks ahead of schedule.
• The clinical trials are designed to evaluate the safety and immunogenicity of Fluviral in healthy adults and support accelerated approval in the United States.

Sources:

• Health & Medicine Week editors from staff and other reports.
• Copyright 2005, Health & Medicine Week via NewsRx.com.